| abstract |
The present invention provides that a combination therapy using at least in part a GITR binding molecule, eg, an anti-GITR antibody, and at least one additional agent (eg, a chemotherapeutic agent) that is not a GITR binding molecule treats cancer And / or based on the discovery that it is more effective than the administration of an agent without a GITR binding molecule in preventing and / or reducing the size of a particular tumor. The present invention provides combination therapy using a GITR binding molecule in combination with one or more additional agents. |